Analyst Price Targets — KPTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 31, 2026 10:08 am | Robert Burns | H.C. Wainwright | $3.00 | $7.01 | TheFly | Karyopharm downgraded to Neutral from Buy at H.C. Wainwright |
| July 31, 2026 8:39 am | — | Robert W. Baird | $3.00 | $7.01 | TheFly | Karyopharm downgraded to Neutral from Outperform at Baird |
| July 21, 2026 11:56 am | Brian Abrahams | RBC Capital | $16.00 | $8.11 | StreetInsider | RBC Capital on Karyopharm Therapeutics (KPTI): 'See Buying Oppty On Weakness' |
| May 6, 2026 10:13 am | — | H.C. Wainwright | $13.00 | $9.41 | TheFly | Karyopharm price target raised to $13 from $8 at H.C. Wainwright |
| April 27, 2026 10:46 am | — | Piper Sandler | $16.00 | $8.66 | TheFly | Karyopharm price target raised to $16 from $8 at Piper Sandler |
| March 9, 2026 8:20 pm | — | UBS | $28.00 | $8.49 | TheFly | Karyopharm initiated with a Buy at Rodman & Renshaw |
| December 17, 2025 12:01 pm | — | Goldman Sachs | $12.00 | $6.33 | StreetInsider | Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick |
| December 17, 2025 12:01 pm | — | Piper Sandler | $12.00 | $6.33 | StreetInsider | Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick |
| November 4, 2025 2:49 pm | Brian Abrahams | RBC Capital | $19.00 | $5.60 | TheFly | Karyopharm price target lowered to $19 from $30 at RBC Capital |
| October 13, 2025 10:10 am | Robert Burns | H.C. Wainwright | $15.00 | $5.50 | TheFly | Karyopharm upgraded to Buy from Neutral at H.C. Wainwright |
Latest News for KPTI
NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees.
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIOÂ (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated Approval for…
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KPTI.
U.S. House Trading
No House trades found for KPTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.